The diluted atropine for inhibition of myopia progression in Korean children

Ji-Sun Moon¹, Sun Young Shin²

¹Department of Ophthalmology, National Medical Center, 245 Euljiro, Jung-gu, Seoul 04564, Republic of Korea
²Department of Ophthalmology and Visual Science, Seoul St. Mary’s Hospital, College of Medicine, the Catholic University of Korea, Seoul 06591, Republic of Korea

Correspondence to: Sun Young Shin. Department of Ophthalmology and Visual Science, Seoul St. Mary’s Hospital, College of Medicine, the Catholic University of Korea, #222 Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea. eyeshin@catholic.ac.kr

Received: 2018-07-02 Accepted: 2018-08-21

Abstract

- AIM: To evaluate the efficacy and safety of three different concentrations of diluted atropine for the control of myopia in Korean children, and to assess the risk factors associated with rapid myopia progression.
- METHODS: A total of 285 children, with refractive errors within the range of -6 diopters (D) between 5 and 14 years of age were included. After using 0.01%, or 0.025%, or 0.05% atropine, for about 1y, changes in refraction, axial lengths and frequency of adverse events were analyzed. Logistic regression analyses were performed to evaluate the risk factors associated with rapid myopia progression.
- RESULTS: The changes in the mean spherical equivalent values were -0.134 D/mo in the before atropine group, -0.070 D/mo in the 0.01% atropine group, -0.047 D/mo in the 0.05% atropine group, and -0.019 D/mo in the 0.05% atropine group, with significant differences between the groups (P<0.001). The axial elongation was 0.046 mm/mo, 0.037 mm/mo, 0.025 mm/mo, and 0.019 mm/mo respectively, with significant differences between the groups (P=0.003). The incidence of photophobia and near vision difficulty was not different among the three atropine groups (P=0.425 and P=0.356, respectively). Multivariate logistic regression analyses showed that only highly myopic parents were a significant predictive factor of rapid myopia progression in Korean children (odds ratio, 8.155; 95% confidence interval, 3.626-18.342; P<0.001).
- CONCLUSION: Treatment with 0.01%, 0.025% and 0.05% atropine solution inhibits myopia progression in Korean children in a dose-dependent manner. Children with highly myopic parents preferentially shows a rapid myopia progression rate.

KEYWORDS: atropine; Korean children; myopia; progression

DOI:10.18240/ijo.2018.10.13

Citation: Moon JS, Shin SY. The diluted atropine for inhibition of myopia progression in Korean children. Int J Ophthalmol 2018; 11(10):1657-1662

INTRODUCTION

Myopia is a considerable ophthalmic concern. Because pathologic myopia may result in complications such as choroidal neovascularization, retinal detachment, and glaucoma[1-3]. Due to increases in near-distance work and urban lifestyles, the prevalence of myopia has increased in both Asia and Western countries for the last several decades. The prevalence of myopia in some East Asian countries, including the Republic of Korea, has increased up to 90% in young adults[4-6]. Pathologic myopia is estimated to have a global prevalence of 0.9%-3.1%, and it is the cause of low vision in 5.8%-7.8% of Europeans and 12.2%-31.3% of East Asians[7]. Myopia is, therefore, a significant public health problem due to its increasing prevalence, associated visual morbidities, increased social disability, consequential reduction in the quality of life, and its considerable costs for correction. Interventional approaches such as bifocal glasses, progressive lenses, orthokeratology, and anticholinergic eye drops are current methods to suppress the progression of myopia[8-11]. In the latest network Meta-analysis to determine the effectiveness of different interventions in slowing the progression of myopia in children, Huang et al[12] reported that the most effective intervention that showed a significant reduction in myopia progression involved pharmacological agents such as atropine and pirenzepine. Orthokeratology and peripheral defocus modifying contact lenses showed moderate effects, and progressive addition spectacle lenses showed minimal effects[12]. Atropine eye drops are therefore considered the most effective treatment for inhibiting myopia progression. Atropine is a nonselective muscarinic antagonist. The mechanisms in retarding the progression of myopia were based on the inhibition of excessive accommodation and the alternative actions at the retina or the sclera[11,13]. Several studies have reported the effects of atropine on the control of myopia[11-15]. However, there have been no reports on the effects of different concentrations of atropine on Korean
Atropine on myopia progression

children. It is important to determine the atropine effects in different countries and racial groups to confirm whether similar or unique atropine effects exist. It is also important to identify the risk factors associated with myopia progression in children. This study was conducted to evaluate the effect of diluted atropine solution on myopia progression, and to identify the risk factors of rapid progression in Korean children.

SUBJECTS AND METHODS

A total of 285 children with myopia were treated with diluted atropine eye drops, and their medical records were reviewed. This retrospective study adhered to the tenets of the Declaration of Helsinki and was approved by the Institutional Review Board of the Catholic University of Korea, College of Medicine. The Institutional Review Board waived the need to obtain informed consent.

Children with ages between 5-14y with myopia and a spherical equivalent (SE) refractive error below -6.0 diopters (D) myopia were included in the study. Children with anisometropia of SE > 2.0 D; astigmatism more than -1.5 D; other combined ocular diseases such as strabismus, congenital cataract, glaucoma, corneal scar, optic neuropathy, or traumatic ocular injury, and a history of any ocular surgery were excluded.

Before using atropine, children were regularly followed-up and risk factors for rapid myopia progression were evaluated at the first visit. To confirm the family history, the refractive errors of the parents were also measured. A family history of high myopia was defined when any one of the parents showed more than -6.0 D myopia. After that, we prescribed diluted atropine as a routine clinical treatment with dose selection and follow-up for about 1y according to the protocol of our institution. The 0.01%, 0.025% and 0.05% atropine solutions were prepared by diluting a 1% atropine eye drop solution (Isopto® Atropine, 10 mg/mL; Alcon, Fort Worth, TX, USA) with 0.9% normal saline. The eye drops were used daily before bedtime. The 0.05% atropine was prescribed when the calculated myopia progression rate exceeded -1.50 D/y, the 0.025% atropine was prescribed when the calculated myopia progression rate exceeded -1.00 D/y but less than -1.50 D/y, and 0.01% atropine was prescribed when the calculated myopia progression was below -1.00 D/y.

The refraction was measured in SE of cycloplegic autorefraction. The cycloplegic regimen consisted of three drops of 10 mg/mL cyclopentolate hydrochloride (OcuCyclo®, Samil, Republic of Korea), administered approximately 5min apart. Cycloplegic autorefraction measurements were performed at least 30min after instillation of the third drop of cyclopentolate. A Huvitz HRK-7000A® auto ref-keratometer (Coburn Technologies, South Windsor, CT, USA) was used to take five reliable readings. The results selected for analyses showed the same measurement values at least three times. The main outcome, the rate of refractive growth for all groups was calculated by the formula of McClatchey and Hofmeister to reflect the logarithmic nature of refractive growth:

$$\text{Rate of refractive growth} = \frac{(\text{Refraction}_2 - \text{Refraction}_1)}{\log(\text{Age}_2 + 0.6y)/\log(\text{Age}_1 + 0.6y)}$$

The secondary parameter involved the axial length, which was measured using an IOLMaster® 500 (Carl Zeiss, Jena, Germany). Five measurements were obtained for each eye, and the axial length was calculated using an automated system included with the equipment.

The adverse event was monitored by changes in the near point of accommodation (NPA) and pupil size. The NPA was defined as the closest point at which an object could be seen clearly and measured with the Royal Air Force Rule. The pupil size was measured using a VIP™-200 pupillometer (Neuroptics, Berkeley, CA, USA) in a photopic environment. All measurements of cycloplegic autorefraction, axial length, NPA, and pupil size were performed by investigators who were trained and certified at every visit.

Other examinations included the best-corrected visual acuity using the Snellen eye chart, slit-lamp biomicroscopy and a fundus examination.

Statistical Analysis All measured variables were calculated as the average of both eyes. Data are expressed as the mean±standard deviation or number (percentage) as appropriate. The clinical baseline measurements and demographic characteristics of all groups were evaluated by one-way analysis of variance (ANOVA) for continuous variables and the Chi-square test for categorical variables. The analyses of outcomes were based on an evaluation of the magnitude of change in SE, the rate of refractive growth, and the axial lengths between the follow-up and baseline among all groups using one-way ANOVA with Bonferroni post hoc analyses. Rapid myopia progression was defined as a progression rate of more than -1.0 D/y. The most relevant risk factors associated with rapid myopia progression were selected using univariate logistic regression analyses. Variables with a value of $P<0.2$ using univariate logistic regression were included in the final multivariate logistic regression analyses. In all other analyses, except for univariate logistic regression analyses, a value of $P<0.05$ was considered statistically significant. Statistical analyses were performed using SPSS statistical software for Windows, version 21 (SPSS, Chicago, IL, USA).

RESULTS

Between January 2015 and May 2018, totally 285 children were enrolled and followed-up. Among the 285 children, 89, 63 and 133 children were included in the 0.01%, 0.025% and 0.05% atropine groups, respectively. There was no significant difference in age, sex, family history of high myopia, previous refractive error and an axial length between the three atropine treated groups (Table 1).
The changes in the refraction of the before atropine group, 0.01% atropine group, 0.025% atropine group, and 0.05% atropine group were -0.134±0.160 D/mo, -0.070±0.072 D/mo, -0.047±0.072 D/mo, and -0.019±0.056 D/mo, respectively. There was a statistically significant difference between the four groups according to the concentration of eye drops (P<0.001; Table 2).

Table 2 also shows the rate of refractive growth of the before atropine group, 0.01% atropine group, 0.025% atropine group, and 0.05% atropine group. There was also a statistically significant difference between the four groups according to the concentration of eye drops (P<0.001). As the secondary outcome, the changes in axial length were 0.046±0.020, 0.037±0.027, 0.025±0.020, and 0.019±0.021 mm/mo, respectively, in each group. There was also a statistically significant difference between the four groups according to the concentration of eye drops (P<0.003; Table 2).

We graded the rate of myopia progression as follows: the slowest rate was a change of the calculated refraction less than 0.25 D/y, the moderate rate was between 0.25 and 0.5 D/y, and the fast rate was between 0.5 and 1 D/y. The fastest rate was a calculated change of more than 1 D/y. The fastest myopia progression rates occurred in 66.3% of the before atropine group, 38.2% in the 0.01% atropine group, 34.9% in the 0.025% atropine group, and 6.8% in the 0.05% atropine group. The lowest progression rates of myopia were 8.5%, 24.7%, 30.2% and 58.6%, respectively (Table 3).

Table 4 shows the changes in the NPA and pupil size. There was no statistically significant difference in the frequency of near vision difficulties and photophobia between the three treated groups (P=0.425 and P=0.356, respectively). No serious adverse event related to atropine was reported. There was no deterioration in the best-corrected visual acuity, and no lenticular, optic disc, or macular change was reported. There were no cases of ocular infections and the contamination of diluted atropine during the study period.

The results of the univariate analyses are summarized in Table 5. Age, family history and axial length were selected for inclusion in the multivariate logistic regression analyses. These analyses indicated that only the family history of high myopia was a significant predictive factor of rapid myopia progression in Korean children [odds ratio (OR), 8.155; 95% confidence interval (CI), 3.626-18.342; P<0.001; Table 5].

DISCUSSION
The results of our study indicated that treatment with 0.01%, 0.025% and 0.05% atropine eye drops resulted in both a clinical and statistical reduction in the progression of myopia when compared with before atropine group. The calculated 1-year changes in the refraction of the before atropine, 0.01% atropine, 0.025% atropine, and 0.05% atropine groups were -1.61 D, -0.84 D, -0.56 D and -0.23 D, respectively. In phase 1 of the ATOM 2 study, the myopia progressions were -0.49 D, -0.38 D and -0.30 D in the 0.01%, 0.1%, and 0.5% atropine groups at 24mo, respectively\(^\dagger\). There was a dose-dependent
response to atropine in both studies. The myopia progression rate in 0.01% atropine-treated children was reported as -0.49 D at 2y by Chia et al \[14\], -0.1 D/y by Clark et al \[15\], and -0.84 D/y in our study. Compared with the previous results, the myopia progression rate of Korean children was the fastest. This difference could result from ethnic differences or cultural and/or environmental factors such as more loading near work and less outdoor activity. In this study, the myopia progression rate of 0.05% atropine used children was similar to the rate of children who used 0.01% atropine in the previous study \[14\]. The calculated rate, -0.84 D/y of 0.01% atropine group in our study was similar to that in control (not treated) group from a previous study by Clark \[15\]. This implies that higher concentrations rather than 0.01% atropine may be effective for Korean children.

In this study, we did not randomly select patients when determining the concentration of atropine. Instead, atropine was administered at a higher concentration in patients with rapidly progressing basal myopia progression. This suggests that the effect to inhibition of myopia progression of 0.025% and 0.05% atropine may be more effective than that shown in this study.

In phase 3 of the ATOM 2 study, it was reported that 0.01% atropine was the most effective inhibitor of myopia progression due to a rebound phenomenon after cessation of higher concentrations of atropine \[17\]. However, in Korean children, the myopia progression rate was -0.84 D/y even at 0.01% atropine, requiring higher concentrations of atropine to reduce the myopia progression rate. Therefore, it is recommended to administer higher concentration of atropine initially to Korean children with rapid myopia progression and subsequently taper with lower concentrations to minimize the incidence of rebound phenomenon.

The percentage change of the NPA and pupil size showed no

**Table 3 Distribution of myopia progression rates**

<table>
<thead>
<tr>
<th>Myopia progression rates</th>
<th>Before atropine</th>
<th>0.01% atropine</th>
<th>0.025% atropine</th>
<th>0.05% atropine</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Slowest (change of D/y&lt;0.25)</td>
<td>24 (8.5)</td>
<td>22 (24.7)</td>
<td>19 (30.2)</td>
<td>78 (58.6)</td>
<td></td>
</tr>
<tr>
<td>Moderate (0.25≤ change of D/y&lt;0.50)</td>
<td>32 (11.2)</td>
<td>12 (13.5)</td>
<td>7 (11.1)</td>
<td>20 (15.0)</td>
<td></td>
</tr>
<tr>
<td>Faster (0.50≤ change of D/y&lt;1)</td>
<td>40 (14.0)</td>
<td>21 (23.6)</td>
<td>15 (23.8)</td>
<td>26 (19.6)</td>
<td></td>
</tr>
<tr>
<td>Fastest (change of D/y≥1)</td>
<td>189 (66.3)</td>
<td>34 (38.2)</td>
<td>22 (34.9)</td>
<td>9 (6.8)</td>
<td></td>
</tr>
</tbody>
</table>

D: Diopters. Data are expressed as a number (percentage).

**Table 4 Changes in accommodation and pupil size**

<table>
<thead>
<tr>
<th>Variables</th>
<th>0.01% atropine</th>
<th>0.025% atropine</th>
<th>0.05% atropine</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accommodation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NPA before atropine use (cm)</td>
<td>7.7±3.8</td>
<td>7.5±2.2</td>
<td>7.1±2.6</td>
<td>0.447</td>
</tr>
<tr>
<td>NPA after atropine use (cm)</td>
<td>8.7±2.6</td>
<td>9.4±2.8</td>
<td>10.1±4.4</td>
<td>0.142</td>
</tr>
<tr>
<td>NPA change (%)</td>
<td>15.2±52.4</td>
<td>23.4±42.8</td>
<td>26.5±59.4</td>
<td>0.113</td>
</tr>
<tr>
<td>Near vision difficulty (%)</td>
<td>1 (1.1)</td>
<td>2 (3.2)</td>
<td>10 (7.5)</td>
<td>0.425</td>
</tr>
<tr>
<td>Pupil size</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pupil size before atropine use (mm)</td>
<td>5.1±0.4</td>
<td>5.2±0.7</td>
<td>5.3±1.1</td>
<td>0.126</td>
</tr>
<tr>
<td>Pupil size after atropine use (mm)</td>
<td>5.9±0.9</td>
<td>6.2±0.7</td>
<td>6.4±0.8</td>
<td>0.326</td>
</tr>
<tr>
<td>Pupil size change (%)</td>
<td>13.7±16.8</td>
<td>13.9±20.2</td>
<td>14.7±21.2</td>
<td>0.189</td>
</tr>
<tr>
<td>Photophobia (%)</td>
<td>3 (3.4)</td>
<td>3 (4.8)</td>
<td>14 (10.5)</td>
<td>0.356</td>
</tr>
</tbody>
</table>

NPA: Near point of accommodation. Data are expressed as the mean ± standard deviation or number (percentage), as appropriate.

**Table 5 Univariate and multivariate analyses of the risk factors for rapid progression of myopia**

<table>
<thead>
<tr>
<th>Variables</th>
<th>Univariate analysis</th>
<th>Multivariate analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR 95%CI P</td>
<td>OR 95%CI P</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>M</td>
<td>1.000</td>
<td></td>
</tr>
<tr>
<td>F</td>
<td>0.865 0.483-1.549</td>
<td>0.625</td>
</tr>
<tr>
<td>Age (y)</td>
<td>0.894 0.771-1.037</td>
<td>0.138 0.868 0.679-1.110</td>
</tr>
<tr>
<td>Family history</td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>1.000</td>
<td>1.000</td>
</tr>
<tr>
<td>Yes</td>
<td>9.635 5.006-18.546</td>
<td>&lt;0.001 8.155 3.626-18.342</td>
</tr>
<tr>
<td>Refraction basal</td>
<td>1.070 0.929-1.232</td>
<td>0.349</td>
</tr>
<tr>
<td>Axial length basal</td>
<td>0.779 0.561-1.082</td>
<td>0.136 0.911 0.595-1.397</td>
</tr>
</tbody>
</table>
had high myopia, their children's myopia progression rate
confirmed that when parents
5.5 (95% CI, 3.2-12.6). A strong association between parental
3.7 (95% CI, 1.1-6.5) and the OR of having high myopia was
of the children developing mild or moderate myopia was 2.5-
confirmed that when there was a high myopic parent, the OR
birth weight
Gong
Adverse events were more frequent in the higher concentration
effects, so percentages as high as 0.05% can be used relatively
safely.
Many genetic and environmental parameters/experiences have
been shown to be associated with the prevalence of myopia,
including higher education, a large amount of near work,
socioeconomic status, the level of outdoor activity, and a low
weight. A family history of myopia and ethnicity
are also recognized as risk factors for myopia. Liang et al.[80]
confirmed that when there was a high myopic parent, the OR
of the children developing mild or moderate myopia was 2.5-
3.7 (95% CI, 1.1-6.5) and the OR of having high myopia was
5.5 (95% CI, 3.2-12.6). A strong association between parental
myopia and the axial length in their children was also found. A
23-year clinical follow-up study confirmed that when parents
had high myopia, their children's myopia progression rate
was faster and the final adulthood SE was more myopic.[31]
In the present study, the factors associated with rapid myopia
progression were also analyzed. Age, sex, a degree of basal
refraction, and axial length were not associated with the rate of
myopia progression. Only a family history of high myopia was
associated with rapid myopia progression (OR, 8.155; 95% CI,
3.626-18.342; \(P<0.001\)). It is still possible that the association
with parental myopia is, at least in part, the result of shared
environmental influences. Despite considerable missing data
for this parameter, our estimates of the effect of parents and
high myopia were consistent with previous studies. Children
with high myopic parents were more likely to have rapid
myopia progression and were more appropriate candidates for
the use of diluted atropine.
There were several limitations in this study. This study was
a retrospective study conducted by a single institution. The
study population of this study is quite homogeneous, and
the sample size of each atropine treated group is different.
However, we performed a comparative study using three
different concentrations of diluted atropine to reveal the dose-
response relationship, which is a strength. To better understand
the relationships between different concentrations and their
effects, we should conduct a prospective study using atropine
at additional concentrations between 0.01%-0.05%.
In summary, this study showed that the use of diluted atropine
solutions inhibited myopia progression in a dose-dependent
manner in Korean children. Korean children need appropriate
strategies involving the appropriate concentration of atropine
eye drops and the optimal duration of use for myopia control.
Furthermore, patients with a family history of high myopia
need to be treated with higher concentrations of atropine to
prevent rapid myopia progression.

ACKNOWLEDGEMENTS

Foundation: Supported by the Catholic Medical Center
Research Foundation made in the program year of 2018 (No.5-
2018-B0001-00006).

Conflicts of Interest: Moon JS, None; Shin SY, None.

REFERENCES

Visual acuity outcomes of ranibizumab treatment in pathologic myopic
eyes with macular retinoschisis and choroidal neovascularization. Retina
RB, Ritch R. Association of myopia with peripapillary perfused capillary
density in patients with glaucoma: an optical coherence tomography
4. Lin LL, Shih YF, Tsai CB, Chen CJ, Lee LA, Hung PT, Hou PK.
Epidemiologic study of ocular refraction among schoolchildren in Taiwan
explain ethnic differences in myopia prevalence? A population-based
6. Jung SI, Han J, Kwon JW, Kim DG, Kim DH, Lim HT. Analysis of
myopic progression in childhood using the Korea national health and
nutrition examination survey. Journal of the Korean Ophthalmological
Society 2016;57(9):1430-1434.
Hayashi W, Yasuzumi K, Nagaoka N, Saka N, Yoshida T, Tokoro T,
Mochizuki M. Long-term pattern of progression of myopic maculopathy:
8. Cheng D, Woo GC, Drobe B, Schmid KL. Effect of bifocal and
prismatic bifocal spectacles on myopia progression in children: three-year
MC, Manny R, Marsh-Tootle W, Scheiman M. A randomized clinical
trial of progressive addition lenses versus single vision lenses on the
1492-1500.
(ROMIO) study: a 2-year randomized clinical trial. Invest Ophthalmol Vis
Atropine on myopia progression


15 Clark TY, Clark RA. Atropine 0.01% eyedrops significantly reduce the progression of childhood myopia. *J Ocul Pharmacol Ther* 2015;31(9):541-545.


